Adi Diab

17PUBLICATIONS
256CO-AUTHORS
Tumour immunologyCancer geneticsGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 06, 2025
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).

Adi Diab, Paolo A Ascierto, Michele Maio

|Oct 25, 2024
Development of an Educational Website for Patients With Cancer and Preexisting Autoimmune Diseases Considering Immune Checkpoint Blockers: Usability and Acceptability Study.

Maria A Lopez-Olivo, Maria E Suarez-Almazor, Gabrielle F Duhon

|Aug 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.

Adi Diab, Helen Gogas, Shahneen Sandhu

|Jun 16, 2023
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.

Faisal Fa'ak, Maryam Buni, Adewunmi Falohun

|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

Talal El Zarif, Amin H Nassar, Elio Adib

|Feb 24, 2023
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial.

A S Feils, A K Erbe, J Birstler

Pageof 3

Frequent Collaborators

4 joint publications

Jennifer A Wargo

4 joint publications

Hussein Tawbi

3 joint publications

Vancheswaran Gopalakrishnan

3 joint publications

Michael T Tetzlaff